Biophytis Annual General Meeting
Find all the documents related to the General Meetings 2021 2020
DetailsBiophytis Annual General Meeting
Biophytis Annual General Meeting We are pleased to invite you to the Biophytis Combined General Meeting which will be held following a second call in closed session on May 10 at 5:00 pm CET. The Combined General Meeting will be broadcast live (audio webcast) in two sessions: At 5pm CET in French, At 6pm CETin…
DetailsLive Stock Price
Live Stock Price
COVID-19: COVA clinical program
SEVERE ACUTE RESPIRATORY INFECTIONS: COVA CLINICAL PROGRAMME 1. Respiratory infections such as Covid-19 cause many hospital admissions and deaths According to the World Health Organisation (WHO), viral respiratory infections kill thousands of patients worldwide every year. In 2023, more than 230,000 patients died from COVID-19, out of a total of almost 7 million…
Details
2020
Posters & Publications 2020 SARA program: the use of BIO101, a MAS receptor agonist, for the treatment of sarcopenia. Industry sponsored session, annual digital meeting of the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD). Tourette et al. SARA program: Preliminary Findings & Implications from SARA-OBS Study and Its Impact on SARA-INT Study. Dioh et al.…
DetailsSEC Filings
SEC Filings Filing Date Form Description January 14, 2025 6-K On January 14, 2025, Biophytis S.A. issued a press release announcing that the company enters exclusive negotiations with a Chinese pharmaceutical company to license BIO101. January 6, 2025 6-K On January 6, 2025, Biophytis S.A. (the “Company”) issued a press release announcing the temporary suspension…
DetailsAMF Regulated Information
Regulated Information In French: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 décembre 2024 In French: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 octobre 2024 In French: Information mensuelle relative au nombre total des…
Details
2014
Posters & Publications 2014 The SARCOB program: a french consortium for developing drug candidate and nutraceutical targeting sarcopenic obesity. Dioh et al. Poster presentation at the 5th International Conference on Frailty & Sarcopenia Research (ICFSR), March 12-14, 2014, Barcelona, Spain. Abstract published in The Journal of Frailty & Aging, 3(1), 72-73, Abstract P186.
Details
2015
Posters & Publications 2015 BIO101, a drug candidate targeting sarcopenic obesity through MAS receptor activation. Raynal et al. Poster presentation at the 8th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 4-6, 2015, Paris, France. Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 6(4), 429. Abstract 1-76.
Details
2016
Posters & Publications 2016 BIO101, a drug candidate targeting Mas Receptor for the treatment of age-related muscle degeneration. From molecular target identification to clinical development. Dilda et al. Poster presentation at the 9th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 10-11, 2016, Berlin, Germany. Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 7(5), 655. Abstract 4-01. A…
Details